MRTNZ Investment Office · S&P 500 · The 360 Vantage
AMGN · NASDAQ-GS
Amgen Inc.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Reference price$393.10As of Jul 28, 2026
Street view
Analyst targets
Published sell-side aggregation—not an MRTNZ forecast.
Forward calendar
Current earnings expectations
Consensus may change until the company reports.
Dec 2026$22.31Street EPS consensus
Dec 2027$23.86Street EPS consensus
Dec 2028$24.32Street EPS consensus
Reported results
Annual financial snapshot
Fiscal period ended Dec 31, 2025.
MetricCurrentPrior
Revenue+10.0% YoY$36.75B$33.42B
Operating income$9.08B$7.26B
Net income$7.71B$4.09B
Operating cash flow$9.96B$11.49B
Capital expenditures($1.86B)($1.1B)
Current context
Related news
Company-linked articles surfaced by Nasdaq.
Evidence
Sources & method
Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →
Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.